Reactivation of Varicella Zoster Virus and Risk of Vascular Disease

Brief Title

Reactivation of Varicella Zoster Virus and Risk of Vascular Disease

Official Title

Reactivation of Varicella Zoster Virus and Risk of Vascular Disease in the Health Survey for England: a Nested Case Control Study

Brief Summary

      The purpose of this study is to investigate whether there is an association between stroke or
      heart attack and reactivation of varicella zoster virus, measured by antibody levels, using
      linked data from the Health Survey for England and secondary care.

Detailed Description

      This study will use a case control design to investigate whether adult participants in the
      Health Survey for England between 2009 and 2013 who were admitted to hospital with either a
      stroke or heart attack had higher preceding levels of varicella zoster virus antibodies
      measured in stored serum samples compared to matched controls with no history of heart attack
      or stroke, controlling for a range of potential demographic, lifestyle and clinical

      This study is funded by the University College London Hospitals Biomedical Research Centre
      Fast Track grant scheme and has received ethics approval (ref 15/NW/0456).

Study Type


Primary Outcome

Odds ratio for the effect of high serum antibody titre on stroke or other vascular outcomes

Secondary Outcome

 Prevalence of age- and sex-specific serum VZV antibody titres as a marker for virus reactivation


Varicella Zoster

Study Arms / Comparison Groups

Description:  Adults (aged 16+) with stored serum samples collected for the Health Survey for England (HSE) between 2009 and 2013, who have a record of hospitalisation for stroke, transient ischaemic attack or myocardial infarction occurring after their participation in the HSE.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

June 2015

Completion Date

January 2019

Primary Completion Date

January 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Previous participant in the HSE between 2009 and 2013 with stored serum available.

          -  Either a record of stroke or TIA or MI in linked HES data between 01/01/2009 and
             31/12/2013 or selected as a matched control for those with a record of stroke/ TIA/MI
             in HES data.

          -  Male or female, aged 16 years or above.

        Exclusion Criteria:

          -  HSE participant with no stored serum sample




16 Years - N/A

Accepts Healthy Volunteers



Charlotte Warren-Gash, MRCP PhD, , 

Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

University College, London

Study Sponsor

Charlotte Warren-Gash, MRCP PhD, Principal Investigator, UCL

Verification Date

January 2019